



# Financial tear sheet

## Corporate Profile

2015 was a pivotal year for Baxter: In July we executed the spinoff of our BioScience business. The corporate separation created value for investors and resulted in a Baxter portfolio focused solely on the Hospital Products and Renal technologies central to our core identity. Today we are collaborating around the world to shape a leaner, more efficient company, positioned to deliver on our mission and succeed on behalf of all our stakeholders well into the future.

## Stock Information

BAX (BAX)	
<b>Exchange</b>	NYSE (US Dollar)
<b>Price</b>	\$63.59
<b>Change (%)</b>	▲ 0.12 (0.19%)
<b>Volume</b>	2,738,550
<b>52 Week Low</b>	\$43.13
<b>Market Cap</b>	\$34,648,341,421
<b>Rolling EPS</b>	1.64
<b>PE Ratio</b>	38.7109
<b>Shares Outstanding</b>	544,870,914
Data as of 10/20/2017 4:01 PM ET	



Data provided by Nasdaq. Minimum 15 minutes delayed.

## Latest News

DATE	TITLE
10/16/17	Baxter to Present at the Credit Suisse 26th Annual Healthcare Conference
10/12/17	Baxter Provides Update on Puerto Rico Recovery Status Post Hurricane Maria
10/03/17	Baxter Enrolls First Patients in U.S. and Colombia Clinical Trials for HDx Therapy Enabled by THERANOVA

## Recent & Upcoming Events

DATE	TITLE
09/06/2017 7:45 AM CT	Goldman Sachs 14th Annual European Medtech and Healthcare Services Conference
09/11/2017 1:40 PM ET	Morgan Stanley 15th Annual Global Healthcare Conference <b>Location</b> New York
10/25/2017 8:30 AM ET	Q3 2017 Baxter International Inc. Earnings Conference Call

## SEC Filings

FILING DATE	FORM
09/07/17	4
09/07/17	4
09/06/17	4
09/06/17	4

## Primary IR Contact

Clare Trachtman  
Baxter International Inc.  
**Phone:** 224-948-3085